Regulatory
Regulatory submissions, compliance, and agency guidance.
Regulatory
Aug 25, 2026
ANDA Submission — Key Components and Common Deficiencies
What an ANDA submission needs to include, and the deficiencies FDA cites most often.
5
Regulatory
Aug 25, 2026
Drug Master File (DMF) — Purpose and Submission Requirements
What a Drug Master File is for and what an API manufacturer needs to include when filing one.
Regulatory
Aug 25, 2026
EU Marketing Authorization — Centralized vs National Procedure
How the centralized, decentralized, and mutual recognition procedures differ for EU marketing authorization.
Regulatory
Aug 25, 2026
GMP Inspection Readiness — Common FDA 483 Observations
The most common categories of FDA 483 observations and how facilities prepare to avoid them.
Regulatory
Aug 25, 2026
ICH Common Technical Document (CTD) — Module Structure Overview
How the five CTD modules are organized and what each is expected to contain.
Regulatory
Aug 25, 2026
Orphan Drug Designation — Regulatory Pathway Overview
What orphan drug designation requires and the incentives it provides during development.
Regulatory
Aug 25, 2026
Pharmacovigilance Requirements — Post-Marketing Safety Reporting Overview
Core post-marketing safety reporting obligations once a product is on the market.
Regulatory
Aug 25, 2026
Post-Approval Changes: FDA Reporting Categories (PAS, CBE-30, CBE-0, Annual Report)
How FDA classifies post-approval manufacturing changes under 21 CFR 314.70, and what reporting each category requires.
Regulatory
Aug 25, 2026
Regulatory Labeling Requirements — SmPC and Package Insert Content
What must appear in a Summary of Product Characteristics and package insert, and how they differ by region.
Regulatory
Aug 25, 2026
WHO Prequalification — Requirements for API Manufacturers
What API manufacturers need to demonstrate to achieve WHO Prequalification status.
1